Phaseline

Targets › ITGB8

ITGB8 (Integrin beta-8): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Integrin alpha-V:beta-8 (ITGAV:ITGB8) is a receptor for fibronectin. It recognizes the sequence R-G-D in its ligands. (UniProt, P26012)

Open in Phaseline: the race on ITGB8, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Corbus PharmaceuticalsCRB-601
αvβ8 integrin antagonist monoclonal antibody
ITGAV, ITGB8Phase 1Solid TumorDec 2026

Conditions

Solid Tumor (1)

Modalities

antibody (1)

Companies

Corbus Pharmaceuticals (1)

Related targets

ITGAV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.